Clinical trial
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent…
NCT00072176 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00072176 |
|---|---|
| Title | Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer |
| Official title | A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma, Stage IIIA Endometrial Carcinoma, Stage IIIB Endometrial Carcinoma, Stage IIIC Endometrial Carcinoma, Stage IVA Endometrial Carcinoma, Stage IVB Endometrial Carcinoma |
| Intervention type | Drug, Other |
| Interventions | temsirolimus, laboratory biomarker analysis |
| Enrollment | 62 |
| Start date | May 1, 2004 |
| Primary completion | May 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Nov 6, 2003 |
| Last update posted | Feb 23, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: